Cargando…

Development of modern immunization agent against bovine papillomavirus type 1 infection based on BPV1 L1 recombinant protein

Bovine papillomavirus type 1 L1 protein was produced in a baculovirus expression system and purified as virus-like particles (VLPs) by affinity chromatography using lectins. The morphological integrity of VLPs was confirmed by electron microscopy. Differences between the two detected variants were d...

Descripción completa

Detalles Bibliográficos
Autores principales: Vrablikova, Alena, Brezani, Veronika, Psikal, Ivan, Fraiberk, Martin, Sebela, Marek, Fojtikova, Martina, Kulich, Pavel, Hezova, Renata, Masek, Josef
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10086343/
https://www.ncbi.nlm.nih.gov/pubmed/37056230
http://dx.doi.org/10.3389/fvets.2023.1116661
_version_ 1785022131111723008
author Vrablikova, Alena
Brezani, Veronika
Psikal, Ivan
Fraiberk, Martin
Sebela, Marek
Fojtikova, Martina
Kulich, Pavel
Hezova, Renata
Masek, Josef
author_facet Vrablikova, Alena
Brezani, Veronika
Psikal, Ivan
Fraiberk, Martin
Sebela, Marek
Fojtikova, Martina
Kulich, Pavel
Hezova, Renata
Masek, Josef
author_sort Vrablikova, Alena
collection PubMed
description Bovine papillomavirus type 1 L1 protein was produced in a baculovirus expression system and purified as virus-like particles (VLPs) by affinity chromatography using lectins. The morphological integrity of VLPs was confirmed by electron microscopy. Differences between the two detected variants were deciphered by mass spectrometry of peptides (MALDI-TOF). Mice were immunized with purified VLPs in doses of 10, 25, or 50 μg in combination with 1% saponin and 15% alhydrogel per dose as adjuvants. Analysis of the humoral immune response revealed increased levels of specific antibodies detected 3 weeks after the first immunization in all groups of animals. This was further significantly increased by the booster applied 3 weeks after the first dose, with the best immune response in a group of mice immunized by the largest dose of antigen. BPV1 L1 VLPs purified by affinity chromatography using lectins could be used for prophylactic immunization in veterinary medicine.
format Online
Article
Text
id pubmed-10086343
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-100863432023-04-12 Development of modern immunization agent against bovine papillomavirus type 1 infection based on BPV1 L1 recombinant protein Vrablikova, Alena Brezani, Veronika Psikal, Ivan Fraiberk, Martin Sebela, Marek Fojtikova, Martina Kulich, Pavel Hezova, Renata Masek, Josef Front Vet Sci Veterinary Science Bovine papillomavirus type 1 L1 protein was produced in a baculovirus expression system and purified as virus-like particles (VLPs) by affinity chromatography using lectins. The morphological integrity of VLPs was confirmed by electron microscopy. Differences between the two detected variants were deciphered by mass spectrometry of peptides (MALDI-TOF). Mice were immunized with purified VLPs in doses of 10, 25, or 50 μg in combination with 1% saponin and 15% alhydrogel per dose as adjuvants. Analysis of the humoral immune response revealed increased levels of specific antibodies detected 3 weeks after the first immunization in all groups of animals. This was further significantly increased by the booster applied 3 weeks after the first dose, with the best immune response in a group of mice immunized by the largest dose of antigen. BPV1 L1 VLPs purified by affinity chromatography using lectins could be used for prophylactic immunization in veterinary medicine. Frontiers Media S.A. 2023-03-28 /pmc/articles/PMC10086343/ /pubmed/37056230 http://dx.doi.org/10.3389/fvets.2023.1116661 Text en Copyright © 2023 Vrablikova, Brezani, Psikal, Fraiberk, Sebela, Fojtikova, Kulich, Hezova and Masek. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Veterinary Science
Vrablikova, Alena
Brezani, Veronika
Psikal, Ivan
Fraiberk, Martin
Sebela, Marek
Fojtikova, Martina
Kulich, Pavel
Hezova, Renata
Masek, Josef
Development of modern immunization agent against bovine papillomavirus type 1 infection based on BPV1 L1 recombinant protein
title Development of modern immunization agent against bovine papillomavirus type 1 infection based on BPV1 L1 recombinant protein
title_full Development of modern immunization agent against bovine papillomavirus type 1 infection based on BPV1 L1 recombinant protein
title_fullStr Development of modern immunization agent against bovine papillomavirus type 1 infection based on BPV1 L1 recombinant protein
title_full_unstemmed Development of modern immunization agent against bovine papillomavirus type 1 infection based on BPV1 L1 recombinant protein
title_short Development of modern immunization agent against bovine papillomavirus type 1 infection based on BPV1 L1 recombinant protein
title_sort development of modern immunization agent against bovine papillomavirus type 1 infection based on bpv1 l1 recombinant protein
topic Veterinary Science
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10086343/
https://www.ncbi.nlm.nih.gov/pubmed/37056230
http://dx.doi.org/10.3389/fvets.2023.1116661
work_keys_str_mv AT vrablikovaalena developmentofmodernimmunizationagentagainstbovinepapillomavirustype1infectionbasedonbpv1l1recombinantprotein
AT brezaniveronika developmentofmodernimmunizationagentagainstbovinepapillomavirustype1infectionbasedonbpv1l1recombinantprotein
AT psikalivan developmentofmodernimmunizationagentagainstbovinepapillomavirustype1infectionbasedonbpv1l1recombinantprotein
AT fraiberkmartin developmentofmodernimmunizationagentagainstbovinepapillomavirustype1infectionbasedonbpv1l1recombinantprotein
AT sebelamarek developmentofmodernimmunizationagentagainstbovinepapillomavirustype1infectionbasedonbpv1l1recombinantprotein
AT fojtikovamartina developmentofmodernimmunizationagentagainstbovinepapillomavirustype1infectionbasedonbpv1l1recombinantprotein
AT kulichpavel developmentofmodernimmunizationagentagainstbovinepapillomavirustype1infectionbasedonbpv1l1recombinantprotein
AT hezovarenata developmentofmodernimmunizationagentagainstbovinepapillomavirustype1infectionbasedonbpv1l1recombinantprotein
AT masekjosef developmentofmodernimmunizationagentagainstbovinepapillomavirustype1infectionbasedonbpv1l1recombinantprotein